Abstract
To the Editor: The use of statins after aneurysmal subarachnoid hemorrhage (SAH) has a strong scientific rationale and appears promising in preliminary clinical studies.1–2 However, the assertion by Sillberg et al that their meta-analysis “supports the routine use of statins” is too strong.3 This conclusion was based on the cumulative experience from three small single-center clinical trials involving a total of only 158 patients. The purported reduction in mortality (reported in only 2/3 trials) was based on 11 deaths among control patients compared with 2 deaths among statin-treated patients. Because of the small numbers, this finding is not particularly robust—if there had been, for example, one less death in the …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
